NETSPOT (68ga-dotatate) by Novartis is 68 dotatate binds to somatostatin receptors, with highest affinity for subtype 2 receptors (sstr2). First approved in 2016.
Drug data last refreshed 16h ago · AI intelligence enriched 1mo ago
NETSPOT is a 68Gallium-DOTATATE radiopharmaceutical diagnostic agent approved in 2016 for PET imaging of somatostatin receptor-positive neuroendocrine tumors. It binds with high affinity to somatostatin receptor subtype 2 (SSTR2), which is overexpressed on malignant neuroendocrine cells, enabling detection and localization via positron emission tomography.
Product is at peak commercial maturity with 8+ years post-approval; mature commercial infrastructure with stable field and marketing operations.
68 dotatate binds to somatostatin receptors, with highest affinity for subtype 2 receptors (SSTR2). It binds to cells that express somatostatin receptors, including malignant cells, which overexpress SSTR2. Gallium-68 is a β+ emitting radionuclide with an emission yield that allows PET imaging.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Comparison of Al18F-NOTA-LM3 With 68Ga-DOTATATE and 68Ga-NODAGA-LM3 PET/CT in Patients With Well-differentiated Neuroendocrine Tumors
68Ga-DOTATATE PET/CT in Neuroendocrine Tumor
68Ga-DOTATATE PET-CT for Diagnosis of Neuroendocrine Tumors (NETs)
68Ga-DOTATATE PET/CT in Oncogenic Osteomalacia
Worked on NETSPOT at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on NETSPOT offers stable, mature-stage product experience within Novartis's oncology/nuclear medicine division. Career growth will focus on lifecycle extension strategies, international expansion, and preparation for competitive genericization post-2032.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/mo